new studies obtained after publication of the original Advisory. 48
The original Advisory was developed by an ASA appointed a Task Force of 10 members, including 49 anesthesiologists in both private and academic practice from various geographic areas of the United 50
States and two consulting methodologists from the ASA Committee on Standards and Practice 51
Parameters. 52
The Task Force developed the original Advisory by means of a seven-step process. First, they 53 reached consensus on the criteria for evidence. Second, a systematic review and evaluation was 54 performed on original published research studies from peer-reviewed journals relevant to infectious 55 complications associated with neuraxial techniques. Third, a panel of expert consultants was asked to 56 participate in opinion surveys on the effectiveness of various strategies for prevention, diagnosis, and 57 management of infectious complications associated with neuraxial techniques, and to review and 58 PRACTICE ADVISORY 1/17/2016 5 specifically to the strength and quality of the summarized study findings (i.e., statistical findings, type 81 of data, and the number of studies). In this document, only the highest level of evidence is included in 82 the summary report for each intervention-outcome pair, including a directional designation of benefit, 83 harm, or equivocality for each outcome. Inferred findings are given a directional designation of beneficial (B), harmful (H), or equivocal (E). 95 For studies that report statistical findings, the threshold for significance is p < 0.01. 96 Level 1: The literature contains observational comparisons (e.g., cohort, case-control research 97 designs) with comparative statistics between clinical interventions for a specified clinical outcome. 98 Level 2: The literature contains non-comparative observational studies with associative statistics 99 (e.g., relative risk, correlation, sensitivity/specificity). 100
Level 3: The literature contains noncomparative observational studies with descriptive statistics 101 (e.g., frequencies, percentages). 102 § All meta-analyses are conducted by the ASA methodology group. Meta-analyses from other sources are reviewed but not included as evidence in this document. cannot be used to assess relationships among clinical interventions and outcomes because a clear 106 interpretation of findings is not obtained due to methodological concerns (e.g., confounding of study 107 design or implementation) or the study does not meet the inclusion criteria for content as defined in the 108 "Focus" of the Advisory. 109
Opinion-Based Evidence. All opinion-based evidence (e.g., survey data, open-forum testimony, 110
internet-based comments, letters, and editorials) relevant to each topic was considered in the 111 development of this updated Advisory. However, only the findings obtained from formal surveys are 112 reported in the current update. 113 Opinion surveys were developed to address each clinical intervention identified in the document. 114 Identical surveys were distributed to expert consultants and a random sample of ASA members. 36 Three nonrandomized comparative studies report no statistically 169 significant (p > 0.01) differences in bacterial colonization of the catheter tip when the lumbar insertion 170 site is compared with the caudal insertion site (Category B1-E evidence).
37-39 171
Survey findings: Both the consultants and ASA members strongly agree that, for patients at risk of 172 infectious complications, the decision to select a neuraxial technique should be determined on a case-173 by-case basis. The consultants agree and ASA members strongly agree that, for these patients, 174
alternatives to neuraxial techniques should be considered. Moreover, both the consultants and ASA 175 members strongly agree that the evolving medical status of the patient should be considered in the 9 selection of neuraxial technique. Both the consultants and ASA members strongly agree that a lumbar 177 puncture should be avoided in a patient with a known epidural abscess. 178
Prophylactic antibiotic therapy. 179
Literature findings: The literature is insufficient to assess whether prophylactic antibiotic therapy 180 for known or suspected bacteremic patients reduces the risk of infectious complications associated 181 with neuraxial techniques. Case reports indicate that infectious complications in these patients may 182 still occur even when prophylactic antibiotic therapy is administered (Category B4-E evidence). 12 povidone-iodine; nor is a difference reported when alcohol is added to these skin disinfectants 209
(Category A3-E evidence). 74 Additional findings reported in this study comparing chlorhexidine with 210 alcohol or povidone-iodine with alcohol versus these disinfectants alone are also equivocal (Category 211 
A3-E evidence).

233
Both the consultants and ASA members strongly agree that sterile occlusive dressings should be 234 used at the catheter insertion site. 235
Use of a bacterial filter during continuous epidural infusion. 236
Literature findings: No comparative studies were found that indicates whether the use of bacterial 237 filters reduce infectious complications. One nonrandomized comparative study found that use of a 238 bacterial filter during continuous epidural infusion does not reduce the number of positive cultures 239 distal to the filter (Category B1-E evidence). 85 Studies with observational findings indicate that 240 bacterial colonization may still occur in the presence of micropore filters (Category B2-E 241 evidence). 49, 82, 86 In addition, case reports indicate that infectious complications (e.g., epidural abscess) 242 may still occur in the presence of bacterial filters (Category B4-E evidence).  Consider removing unwitnessed accidentally disconnected catheters. 295  Catheters should not remain in situ longer than clinically necessary. 296
Diagnosis of Infectious Complications Associated with Neuraxial Techniques
Topics addressing the diagnosis of infectious complications consist of: (1) periodically checking 297 for signs/symptoms of infection (e.g., erythema, tenderness, and fever), (2) ordering blood tests (e.g., 298
white blood cell count, sedimentation rate, and C-reactive protein), (3) ordering a culture or cerebral 299 spinal fluid analysis, (4) ordering imaging studies (magnetic resonance imaging, computed 300 tomography, and myelography), and (5) The Task Force notes that signs or symptoms can either manifest within a few hours or may not be 310 apparent for weeks after neuraxial administration. 311
Survey findings: Both the consultants and ASA members strongly agree that periodic evaluation of 312 patients for signs and symptoms (e.g., fever, headache, backache, erythema, and tenderness at the 313 insertion site) is essential for the early identification of infectious complications. They agree that signs 314 and symptoms should be assessed once per day, and strongly agree that signs and symptoms should be 315 *** For diagnostic studies, the "B" referring to patient benefit indicates that the disorder may be detectable using the stated diagnostic intervention. 
Management of Infectious Complications 360
Topics addressed with regard to management or treatment of infectious complications includes: (1) 361 administration of antibiotics, (2) collaboration with appropriate specialists to determine optimal 362 nonsurgical treatment, and (3) collaboration with a surgeon to determine whether surgical intervention 363 or percutaneous drainage is necessary. 364
Administration of antibiotics. 365
Literature findings: Case reports indicate that appropriate antibiotic therapy may be an effective 366 treatment for infections (Category B4-B evidence) . reported that the use of either antibiotic therapy, percutaneous drainage, or surgical interventions were 374 equally as effective regarding patient recovery (Category B1-B evidence) . 172 The Task Force believes 375 that consultation with a physician with expertise in the diagnosis and treatment of infectious diseases 376 should be considered. However, the Task Force recognizes that, even with prompt medical 377 intervention, recovery may be poor or incomplete. 378
Survey findings: The consultants agree and ASA members strongly agree that a specialist or 379 physician with expertise in the diagnosis and treatment of infectious diseases should be consulted at 380 the first sign of a serious infection. 381
Collaboration with a surgeon to determine whether surgical intervention is warranted. 382
Literature findings:
No controlled studies were found that reported differences in neurologic 383 outcome associated with either percutaneous drainage or surgical interventions. Case reports indicate 384 
Diagnosis of Infectious Complications Associated with Neuraxial Techniques
 Perform daily evaluation of patients with indwelling catheters for early signs and symptoms (e.g., fever, backache, headache, erythema and tenderness at the insertion site) of infectious complications throughout their stay in the facility. † † † †  To minimize the impact of an infectious complication, promptly attend to signs or symptoms. ‡ ‡ ‡ Ordering, conducting, or requiring routine laboratory studies may not be necessary. § § § The Centers for Disease Control and Prevention and the American Society of Regional Anesthesia and Pain Medicine have also published recommendations regarding asepsis and management of patients undergoing neuraxial techniques. These are available at the CDC (http://www.cdc.gov/ncidod/dhqp/injectionSafetyPractices.html) and ASRA (http://www.asra.com/consensus-statements/3.html) Web sites. **** Consult product labels for instructions regarding the proper use, application and drying time for skin antiseptics. † † † † Immunocompromised patients may not manifest typical signs and symptoms of infection.
 If an infection is suspected:
o Remove an in-situ catheter and consider culturing the catheter tip. o Order appropriate blood tests o Obtain appropriate cultures o If an abscess is suspected or neurologic dysfunction is present, perform imaging studies and promptly obtain consultation with other appropriate specialties.
Management of Infectious Complications
 Administer appropriate antibiotic therapy at the earliest sign or symptom of a serious neuraxial infection.  Consider consultation with a physician with expertise in the diagnosis and treatment of infectious diseases.  If an abscess is present, obtain surgical consultation to determine whether percutaneous drainage of the abscess or surgery (e.g., laminectomy) is warranted. 
Evidence Model
Patients.
Inclusion criteria:  Patients receiving neuraxial techniques.  Patients at increased risk of infectious complications.  Hospital inpatients (e.g., operating rooms, intensive care units, postoperative surgical floors, labor and delivery settings, hospital wards).  Patients in ambulatory care facilities (e.g., pain clinics).
Exclusion criteria:
 Patients with implantable drug delivery systems.  Patients with chronic indwelling neuraxial analgesic delivery systems.
Procedures.
Inclusion criteria:  Inpatient and ambulatory procedures requiring neuraxial administration. Exclusion criteria:  Injection techniques outside the neuraxis (e.g., peripheral nerve blocks, joint and bursal injections). ‡ ‡ ‡ ‡ Unless otherwise specified, outcomes for the listed interventions refer to the occurrence of infectious complications.
Interventions.
Identification of patients at increased risk of infectious complications (e.g., coexisting infections, diabetes, cancer, arthritis, trauma): For the original Advisory, interobserver agreement among Task Force members and two methodologists was established by interrater reliability testing. Agreement levels using a  statistic for two-rater agreement pairs were as follows: (1) 
